氨磺必利与齐拉西酮对女性精神分裂症患者PANSS评分及不良反应的影响比较

Comparison of the Effect of Amisulpride and Ziprasidone on PANSS Scores and Adverse Reactions in Female Patients with Schizophrenia

目的 :比较研究氨磺必利与齐拉西酮对女性精神分裂症患者阳性和阴性症状量表(PANSS)评分及不良反应的影响。方法 :选择2016年5月—2017年8月我院收治的女性精神分裂症患者80例作为研究对象,按随机数字表法分为两组,各40例。对照组给予齐拉西酮(初始剂量为40 mg/d,bid,1周内增加至维持剂量80～160 mg/d,bid)治疗,观察组予以氨磺必利(初始剂量为400 mg/d,qd,1周内增加至维持剂量800～1200 mg/d,bid)治疗,比较两组阳性和阴性症状量表(PANSS)评分与不良反应发生情况。结果:治疗前及治疗后两组PANSS各因子评分、总分比较,差异无统计学意义(P> 0.05);观察组不良反应发生率明显低于对照组,差异有统计学意义(P <0.05);两组治疗总有效率比较,差异无统计学意义(P> 0.05)。结论 :氨磺必利与齐拉西酮治疗女性精神分裂症的疗效相当,但氨磺必利的安全性更高。

Objective:To perform the comparative study of the effect of amisulpride and ziprasidone on the positive and negative symptom scale(PANSS)scores and adverse events in female patients with schizophrenia.Methods:88 female patients with schizophrenia admitted to our hospital from May 2016 to August 2017 were selected as subjects investigated and divided into two groups according to the random number table method,40 cases in each group.The patients in the control group were given ziprasidone(initial dose was 40 mg/day,bid,and increased to maintenance dose 80~160 mg/day,bid,within 1 week),and the patients in the observation group were given amisulpride(initial dose was 400 mg/day,qd,and increased to a maintenance dose of 800-1200 mg/day,bid,within 1 week.The positive and negative symptom scale(PANSS)scores and adverse events were compared between the two groups.Results:There were no statistically significant differences in the scores and total scores of PANSS between the two groups before treatment and after treatment(P>0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the total effective rate between the two groups(P>0.05).Conclusion:Amisulpride and ziprasidone are equally effective in treating female schizophrenia,but amisulpride is safer.